A vital leap forward in cardiac testing
Fast and accurate diagnosis can make all the difference to patients waiting to find out if they've had a heart attack.
When patients present to the emergency department with signs and symptoms that may indicate Myocardial Infarction (MI), every minute waiting on test results comes at a cost. Patients and their families are anxious, and clinicians and laboratory professionals are pressured to identify the problem quickly and accurately.
But many emergency departments today are overcrowded, leaving both patients and providers waiting for answers. How can this be improved? How can we increase efficiency and diagnostic confidence for clinicians?
Having high-sensitivity troponin I testing available at the point of care can transform the way chest pain patients are assessed, providing results you can trust in just 8 minutes-all from a single fingerstick.
With the Atellica VTLi Patient-side Immunoassay Analyzer, clinicians are delivered high-sensitivity cardiac troponin results at the speed of care. Emergency department patient throughput may be improved, enabling earlier intervention for patients with MI as well as faster disposition for those without an MI.
When a patient presents with symptoms of a potential heart attack, achieving favorable outcomes for patients and their families depends on everyone working together with speed and confidence. During those most critical moments, trust, time and resources aren't just valuable-they're vital.
The Atellica® VTLi Patient-side Immunoassay Analyzer, a high-sensitivity troponin I test at the point of care, delivers accurate results in just 8 minutes. By improving patient throughput and accuracy, the analyzer could transform care delivery for millions of patients each year.
“With the Atellica VTLi system, we’re able to improve the patient pathway by combining rapid results with a process redesigned with the use of an ambulatory care area. We can use space more efficiently, and more importantly, we're going to get them out of hospital faster.”
DR. PAUL COLLINSON
Professor of Cardiovascular Biomarkers and Former Consultant in Chemical Pathology at St George’s Hospital.